Section 3 - Collecting and Processing of the Graft

Bensinger, WI, Martin, PJ, Storer, B, Clift, R, Forman, SJ, Negrin, R, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med. 2001; 344(3):175–81.CrossRefGoogle ScholarPubMed

Beyer, J, Schwella, N, Zingsem, J, Strohscheer, I, Schwaner, I, Oettle, H, et al. Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison. J Clin Oncol. 1995; 13(6):1328–35.CrossRefGoogle ScholarPubMed

Hartmann, O, Le Corroller, AG, Blaise, D, Michon, J, Phillip, I, Norol, F, et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial. Ann Intern Med. 1997; 126(8):600–7.CrossRefGoogle ScholarPubMed

Schmitz, N, Linch, DC, Dreger, P, Goldstone, AH, Boogaerts, MA, Ferrant, A, et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet. 1996; 347(8998):353–7.CrossRefGoogle ScholarPubMed

Bender, JG, To, LB, Williams, S, Schwartzberg, LS. Defining a therapeutic dose of peripheral blood stem cells. J Hematother. 1992; 1(4):329–41.CrossRefGoogle ScholarPubMed

Passos-Coelho, JL, Braine, HG, Davis, JM, Huelskamp, AM, Schepers, KG, Ohly, K, et al. Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization. J Clin Oncol. 1995; 13(3):705–14.CrossRefGoogle ScholarPubMed

Gandhi, MK, Jestice, K, Scott, MA, Bloxham, D, Bass, G, Marcus, RE. The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. Bone Marrow Transplant. 1999; 23(1):9–13.CrossRefGoogle ScholarPubMed

Montgomery, M, Cottler-Fox, M. Mobilization and collection of autologous hematopoietic progenitor/stem cells. Clin Adv Hematol Oncol. 2007; 5(2):127–36.Google ScholarPubMed

Weaver, CH, Hazelton, B, Birch, R, Palmer, P, Allen, C, Schwartzberg, L, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood. 1995; 86(10):3961–9.Google ScholarPubMed

Beguin, Y, Baudoux, E, Sautois, B, Fraipont, V, Schaaf-Lafontaine, N, Pereira, M, et al. Hematopoietic recovery in cancer patients after transplantation of autologous peripheral blood CD34+ cells or unmanipulated peripheral blood stem and progenitor cells. Transfusion. 1998; 38(2):199–208.CrossRefGoogle ScholarPubMed

Reiffers, J, Faberes, C, Boiron, JM, Marit, G, Foures, C, Ferrer, AM, et al. Peripheral blood progenitor cell transplantation in 118 patients with hematological malignancies: analysis of factors affecting the rate of engraftment. J Hematother. 1994; 3(3):185–91.CrossRefGoogle ScholarPubMed

Bolwell, BJ, Pohlman, B, Rybicki, L, Sobecks, R, Dean, R, Curtis, J, et al. Patients mobilizing large numbers of CD34+ cells (‘super mobilizers’) have improved survival in autologous stem cell transplantation for lymphoid malignancies. Bone Marrow Transplant. 2007; 40(5):437–41.CrossRefGoogle ScholarPubMed

Pulsipher, MA, Chitphakdithai, P, Logan, BR, Leitman, SF, Anderlini, P, Klein, JP, et al. Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose. Blood. 2009; 114(13):2606–16.CrossRefGoogle ScholarPubMed

Baron, F, Maris, MB, Storer, BE, Sandmaier, BM, Panse, JP, Chauncey, TR, et al. High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation. Leukemia. 2005; 19(5):822–8.Google Scholar

Dreger, P, Kloss, M, Petersen, B, Haferlach, T, Loffler, H, Loeffler, M, et al. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood. 1995; 86(10):3970–8.Google Scholar

Tarella, C, Di Nicola, M, Caracciolo, D, Zallio, F, Cuttica, A, Omede, P. High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization. Bone Marrow Transplant. 2002; 30(11):725–32.CrossRefGoogle ScholarPubMed

Pusic, I, Jiang, SY, Landua, S, Uy, GL, Rettig, MP, Cashen, AF, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant. 2008; 14(9): 1045–56.CrossRefGoogle ScholarPubMed

Fadini, GP, Pucci, L, Vanacore, R, Baesso, I, Penno, G, Balbarini, A, et al. Glucose tolerance is negatively associated with circulating progenitor cell levels. Diabetologia. 2007; 50(10):2156–63.CrossRefGoogle ScholarPubMed

Fadini, GP, Boscaro, E, de Kreutzenberg, S, Agostini, C, Seeger, F, Dimmeler, S, et al. Time course and mechanisms of circulating progenitor cell reduction in the natural history of type 2 diabetes. Diabetes Care. 2010; 33(5):1097–102.CrossRefGoogle ScholarPubMed

Ferraro, F, Lymperi, S, Mendez-Ferrer, S, Saez, B, Spencer, JA, Yeap, BY, et al. Diabetes impairs hematopoietic stem cell mobilization through alteration of niche function. Sci Transl Med. 2011; 3(104):104ra101.CrossRefGoogle Scholar

Heazlewood, SY, Oteiza, A, Cao, H, Nilsson, SK. Analyzing hematopoietic stem cell homing, lodgment and engraftment to better understand the bone marrow niche. Ann N Y Acad Sci. 2014; 1310:119–28.CrossRefGoogle ScholarPubMed

Rettig, MP, Schroeder, MA, DiPersio, JF. Marrow microenvironment and biology of mobilization of stem cells. In: Appelbaum, FR, Forman, SJ, Negrin, RS, Blume, KG, editors. Thomas’ Hematopoietic Cell Transplantation, 5th edition. New Jersey: Wiley-Blackwell; 2013.Google Scholar

Morrison, SJ, Scadden, DT. The bone marrow niche for haematopoietic stem cells. Nature. 2014; 505(7483):327–34.CrossRefGoogle ScholarPubMed

Taichman, RS, Emerson, SG. Human osteoblasts support hematopoiesis through the production of granulocyte colony-stimulating factor. J Exp Med. 1994; 179(5):1677–82.CrossRefGoogle ScholarPubMed

Calvi, LM, Adams, GB, Weibrecht, KW, Weber, JM, Olson, DP, Knight, MC, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003; 425:841–6.CrossRefGoogle ScholarPubMed

Park, D, Spencer, JA, Koh, BI, Kobayashi, T, Fujisaki, J, Clemens, TL, et al. Endogenous bone marrow MSCs are dynamic, fate-restricted participants in bone maintenance and regeneration. Cell Stem Cell. 2012; 10(3):259–72.CrossRefGoogle ScholarPubMed

Zhang, J, Niu, C, Ye, L, Huang, H, He, X, Tong, WG, et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature. 2003; 425(6960):836–41.CrossRefGoogle ScholarPubMed

Kiel, MJ, Yilmaz, OH, Iwashita, T, Yilmaz, OH, Terhorst, C, Morrison, SJ. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell. 2005; 121(7):1109–21.CrossRefGoogle ScholarPubMed

Kiel, MJ, Radice, GL, Morrison, SJ. Lack of evidence that hematopoietic stem cells depend on N-cadherin-mediated adhesion to osteoblasts for their maintenance. Cell Stem Cell. 2007; 1(2):204–17.CrossRefGoogle ScholarPubMed

Visnjic, D, Kalajzic, Z, Rowe, DW, Katavic, V, Lorenzo, J, Aquila, HL. Hematopoiesis is severely altered in mice with an induced osteoblast deficiency. Blood. 2004; 103(9):3258–64.CrossRefGoogle ScholarPubMed

Zhu, J, Garrett, R, Jung, Y, Zhang, Y, Kim, N, Wang, J, et al. Osteoblasts support B-lymphocyte commitment and differentiation from hematopoietic stem cells. Blood. 2007; 109(9):3706–12.CrossRefGoogle ScholarPubMed

Raaijmakers, MH, Mukherjee, S, Guo, S, Zhang, S, Kobayashi, T, Schoonmaker, JA, et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukemia. Nature. 2010; 464(7290):852–7.CrossRefGoogle Scholar

Kiel, MJ, Acar, M, Radice, GL, Morrison, SJ. Hematopoietic stem cells do not depend on N-cadherin to regulate their maintenance. Cell Stem Cell. 2009; 4(2):170–9.CrossRefGoogle Scholar

Greenbaum, AM, Revollo, LD, Woloszynek, JR, Civitelli, R, Link, DC. N-cadherin in osteolineage cells is not required for maintenance of hematopoietic stem cells. Blood. 2012; 120(2):295–302.CrossRefGoogle Scholar

Bromberg, O, Frisch, BJ, Weber, JM, Porter, RL, Civitelli, R, Calvi, LM. Osteoblastic N-cadherin is not required for microenvironmental support and regulation of hematopoietic stem and progenitor cells. Blood. 2012; 120(2):303–13.CrossRefGoogle Scholar

Zhou, X, Zhang, Z, Feng, JQ, Dusevich, VM, Sinha, K, Zhang, H, et al. Multiple functions of Osterix are required for bone growth and homeostasis in postnatal mice. Proc Natl Acad Sci USA. 2010; 107(29):12919–24.CrossRefGoogle ScholarPubMed

Chan, CK, Chen, CC, Luppen, CA, Kim, JB, DeBoer, AT, Wei, K, et al. Endochondral ossification is required for haematopoietic stem-cell niche formation. Nature. 2009; 457:490–4.CrossRefGoogle ScholarPubMed

Sacchetti, B, Funari, A, Michienzi, S, Di Cesare, S, Piersanti, S, Saggio, I, et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell. 2007; 131(2):324–36.CrossRefGoogle ScholarPubMed

Sugiyama, T, Kohara, H, Noda, M, Nagasawa, T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity. 2006; 25(6):977–88.CrossRefGoogle ScholarPubMed

Lo, CC, Fleming, HE, Wu, JW, Zhao, CX, Miake-Lye, S, Fujisaki, J, et al. Live-animal trafficking of individual haematopoietic stem/progenitor cells in their niche. Nature. 2009; 457(7225):92–6.Google Scholar

Sipkins, DA, Wei, X, Wu, JW, Runnels, JM, Cote, D, Means, TK, et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature. 2005; 435(7044):969–73.CrossRefGoogle ScholarPubMed

Mendez-Ferrer, S, Michurina, TV, Ferraro, F, Mazloom, AR, MacArthur, BD, Lira, SA, et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature. 2010; 466:829–34.CrossRefGoogle Scholar

Yao, L, Yokota, T, Xia, L, Kincade, PW, McEver, RP. Bone marrow dysfunction in mice lacking the cytokine receptor gp130 in endothelial cells. Blood. 2005; 106(13):4093–101.CrossRefGoogle ScholarPubMed

Hooper, AT, Butler, JM, Nolan, DJ, Kranz, A, Iida, K, Kobayashi, M, et al. Engraftment and reconstitution of hematopoiesis is dependent on VEGFR2-mediated regeneration of sinusoidal endothelial cells. Cell Stem Cell. 2009; 4(3):263–74.CrossRefGoogle ScholarPubMed

Oguro, H, Ding, L, Morrison, SJ. SLAM family markers resolve functionally distinct subpopulations of hematopoietic stem cells and multipotent progenitors. Cell Stem Cell. 2013; 13(1):102–16.CrossRefGoogle ScholarPubMed

Barker, JE. Early transplantation to a normal microenvironment prevents the development of Steel hematopoietic stem cell defects. Exp Hematol. 1997; 25(6):542–7.Google ScholarPubMed

Tzeng, YS, Li, H, Kang, YL, Chen, WC, Cheng, WC, Lai, DM. Loss of Cxcl12/Sdf-1 in adult mice decreases the quiescent state of hematopoietic stem/progenitor cells and alters the pattern of hematopoietic regeneration after myelosuppression. Blood. 2011; 117(2):429–39.CrossRefGoogle ScholarPubMed

Zou, YR, Kottmann, AH, Kuroda, M, Taniuchi, I, Littman, DR. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature. 1998; 393(6685):595–9.CrossRefGoogle ScholarPubMed

Katayama, Y, Battista, M, Kao, WM, Hidalgo, A, Peired, AJ, Thomas, SA, et al. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell. 2006; 124(2):407–21.CrossRefGoogle ScholarPubMed

Mendez-Ferrer, S, Lucas, D, Battista, M, Frenette, PS. Haematopoietic stem cell release is regulated by circadian oscillations. Nature. 2008; 452(7186):442–7.CrossRefGoogle ScholarPubMed

Katayama, Y, Battista, M, Kao, WM, Hidalgo, A, Peired, AJ, Thomas, SA, et al. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell. 2006; 124(2):407–21.CrossRefGoogle ScholarPubMed

Himburg, HA, Muramoto, GG, Daher, P, Meadows, SK, Russell, JL, Doan, P, et al. Pleiotrophin regulates the expansion and regeneration of hematopoietic stem cells. Nat Med. 2010; 16(4):475–82.CrossRefGoogle ScholarPubMed

Himburg, HA, Harris, JR, Ito, T, Daher, P, Russell, JL, Quarmyne, M, et al. Pleiotrophin regulates the retention and self-renewal of hematopoietic stem cells in the bone marrow vascular niche. Cell Rep. 2012; 2(4):964–75.CrossRefGoogle ScholarPubMed

Petit, I, Szyper-Kravitz, M, Nagler, A, Lahav, M, Peled, A, Habler, L, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol. 2002; 3(7):687–94.CrossRefGoogle ScholarPubMed

Nakamura-Ishizu, A, Okuno, Y, Omatsu, Y, Okabe, K, Morimoto, J, Uede, T, et al. Extracellular matrix protein tenascin-C is required in the bone marrow microenvironment primed for hematopoietic regeneration. Blood. 2012; 119(23):5429–37.CrossRefGoogle ScholarPubMed

Stier, S, Ko, Y, Forkert, R, Lutz, C, Neuhaus, T, Grunewald, E, et al. Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size. J Exp Med. 2005; 201(11):1781–91.CrossRefGoogle ScholarPubMed

Nilsson, SK, Johnston, HM, Whitty, GA, Williams, B, Webb, RJ, Denhardt, DT, et al. Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood. 2005; 106(4):1232–9.CrossRefGoogle ScholarPubMed

Sugimura, R, He, XC, Venkatraman, A, Arai, F, Box, A, Semerad, C, et al. Noncanonical Wnt signaling maintains hematopoietic stem cells in the niche. Cell. 2012; 150(2):351–65.CrossRefGoogle ScholarPubMed

Christopher, MJ, Rao, M, Liu, F, Woloszynek, JR, Link, DC. Expression of the G-CSF receptor in monocytic cells is sufficient to mediate hematopoietic progenitor mobilization by G-CSF in mice. J Exp Med. 2011; 208(2):251–60.CrossRefGoogle ScholarPubMed

Liu, F, Poursine-Laurent, J, Link, DC. Expression of the G-CSF receptor on hematopoietic progenitor cells is not required for their mobilization by G-CSF. Blood. 2000; 95(10):3025–31.Google Scholar

Anderlini, P, Przepiorka, D, Seong, D, Miller, P, Sundberg, J, Lichtiger, B, et al. Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of chargers for the procedures. Transfusion. 1996; 36(7):590–5.CrossRefGoogle Scholar

Stroncek, DF, Clay, ME, Petzoldt, ML, Smith, J, Jaszcz, W, Oldham, FB, et al. Treatment of normal individuals with granulocyte-colony-stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells. Transfusion. 1996; 36(7):601–10.Google ScholarPubMed

Becker, PS, Wagle, M, Matous, S, Swanson, RS, Pihan, G, Lowry, PA, et al. Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): occurrence in an allogeneic donor of peripheral blood stem cells. Biol Blood Marrow Transplant. 1997; 3(1):45–9.Google Scholar

Stroncek, D, Shawker, T, Follmann, D, Leitman, SF. G-CSF-induced spleen size changes in peripheral blood progenitor cell donors. Transfusion. 2003; 43(5):609–13.CrossRefGoogle ScholarPubMed

Rothe, L, Collin-Osdoby, P, Chen, Y, Sunyer, T, Chaudhary, L, Tsay, A, et al. Human osteoclasts and osteoclast-like cells synthesize and release high basal and inflammatory stimulated levels of the potent chemokine interleukin-8. Endocrinology. 1998; 139(10):4353–63.CrossRefGoogle Scholar

Korbling, M, Fliender, TM. History of blood stem cell transplants. Blood stem cell transplants. In: Gale, RP, Juttner, CA, Henon, P, editors. Peripheral blood stem cell autographs. New York: Cambridge University Press; 1994:9.Google Scholar

Blaise, D, Kuentz, M, Fortanier, C, Bourhis, JH, Milpied, N, Sutton, L, et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol. 2000; 18(3):537–46.CrossRefGoogle ScholarPubMed

Couban, S, Simpson, DR, Barnett, MJ, Bredeson, C, Hubesch, L, Howson-Jan, K, et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood. 2002; 100(5):1525–31.CrossRefGoogle ScholarPubMed

Schmitz, N, Beksac, M, Hasenclever, D, Bacigalupo, A, Ruutu, T, Nagler, A, et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood. 2002; 100(3):761–7.CrossRefGoogle ScholarPubMed

Goterris, R, Hernandez-Boluda, JC, Teruel, A, Gomez, C, Lis, MJ, Terol, MJ, et al. Impact of different strategies of second-line stem cell harvest on the outcome of autologous transplantation in poor peripheral blood stem cell mobilizers. Bone Marrow Transplant. 2005; 36(10):847–53.CrossRefGoogle ScholarPubMed

Costa, LJ, Kramer, C, Hogan, KR, Butcher, CD, Littleton, AL, Shoptaw, KB, et al. Pegfilgrastim-versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis. Transfusion. 2012; 52(11):2375–81.CrossRefGoogle ScholarPubMed

Herbert, KE, Gambell, P, Link, EK, Mouminoglu, A, Wall, DM, Harrison, SJ, et al. Pegfilgrastim compared with filgrastim for cytokine-alone mobilization of autologous haematopoietic stem and progenitor cells. Bone Marrow Transplant. 2013; 48(3):351–6.CrossRefGoogle ScholarPubMed

Bruns, I, Steidl, U, Fischer, JC, Raschke, S, Kobbe, G, Fenk, R, et al. Pegylated G-CSF mobilizes CD34+ cells with different stem and progenitor cell subsets and distinct functional properties in comparison with unconjugated G-CSF. Blood (ASH Annual Meeting Abstracts). 2006; 108:Abstract 3382.Google Scholar

Kobbe, G, Bruns, I, Fenk, R, Czibere, A, Haas, R. Pegfilgrastim for PBSC mobilization and autologous haematopoietic SCT. Bone Marrow Transplant. 2009; 43(9):669–77.CrossRefGoogle ScholarPubMed

Sarkar, CA, Lowenhaupt, K, Wang, PJ, Horan, T, Lauffenburger, DA. Parsing the effects of binding, signaling, and trafficking on the mitogenic potencies of granulocyte colony-stimulating factor analogues. Biotechnol Prog. 2003; 19(3):955–64.CrossRefGoogle ScholarPubMed

Morris, ES, MacDonald, KP, Hill, GR. Stem cell mobilization with G-CSF analogs: a rational approach to separate GVHD and GVL? Blood. 2006; 107(9):3430–5.CrossRefGoogle ScholarPubMed

Brown, RA, Adkins, D, Khoury, H, Vij, R, Goodnough, LT, Shenoy, S, et al. Long-term follow-up of high-risk allogeneic peripheral-blood stem-cell transplant recipients: graft-versus-host disease and transplant-related mortality. J Clin Oncol. 1999; 17(3):806–12.CrossRefGoogle ScholarPubMed

Lane, TA, Law, P, Maruyama, M, Young, D, Burgess, J, Mullen, M, et al. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. Blood. 1995; 85(1):275–82.Google ScholarPubMed

Gazitt, Y, Shaughnessy, P, Liu, Q. Differential mobilization of CD34+ cells and lymphoma cells in non-Hodgkin’s lymphoma patients mobilized with different growth factors. J Hematother Stem Cell Res. 2001; 10(1):167–76.Google ScholarPubMed

Devine, SM, Brown, RA, Mathews, V, Trinkaus, K, Khoury, H, Adkins, D, et al. Reduced risk of acute GvHD following mobilization of HLA-identical sibling donors with GM-CSF alone. Bone Marrow Transplant. 2005; 36(6):531–8.CrossRefGoogle ScholarPubMed

Gazitt, Y, Shaughnessy, P, Devore, P. Mobilization of dendritic cells and NK cells in non-Hodgkin’s lymphoma patients mobilized with different growth factors. J Hematother Stem Cell Res. 2001; 10(1):177–86.Google ScholarPubMed

Schroeder, MA, Merida, S, Schwab, D, Rettig, MP, Meier, S, Lopez, S, et al. Sargramostim (GM-CSF) combined with IV Plerixafor to mobilize peripheral blood stem cells (PBSC) from normal HLA-matched allogeneic sibling donors. BMT Tandem “Scientific” Meeting, March, 2014; Session N(Abstract 32):Abstract 32.

Ford, CD, Greenwood, J, Anderson, J, Snow, G, Petersen, FB. CD34+ cell adhesion molecule profiles differ between patients mobilized with granulocyte-colony-stimulating factor alone and chemotherapy followed by granulocyte-colony-stimulating factor. Transfusion. 2006; 46(2):193–8.CrossRefGoogle ScholarPubMed

Milone, G, Leotta, S, Indelicato, F, Mercurio, S, Moschetti, G, Di Raimondo, F, et al. G-CSF alone vs cyclophosphamide plus G-CSF in PBPC mobilization of patients with lymphoma: results depend on degree of previous treatment. Bone Marrow Transplant. 2003; 31(9):747–54.CrossRefGoogle Scholar

Krishnan, A, Bhatia, S, Slovak, ML, Arber, DA, Niland, JC, Nademanee, A, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood. 2000; 95(5):1588–93.Google ScholarPubMed

Desikan, KR, Barlogie, B, Jagannath, S, Vesole, DH, Siegel, D, Fassas, A, et al. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol. 1998; 16(4):1547–53.CrossRefGoogle ScholarPubMed

Koc, ON, Gerson, SL, Cooper, BW, Laughlin, M, Meyerson, H, Kutteh, L, et al. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF. J Clin Oncol. 2000; 18(9):1824–30.CrossRefGoogle ScholarPubMed

Gupta, S, Zhou, P, Hassoun, H, Kewalramani, T, Reich, L, Costello, S, et al. Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: report of a phase II trial. Bone Marrow Transplant. 2005; 35(5):441–7.CrossRefGoogle ScholarPubMed

Hopman, RK, DiPersio, JF. Advances in stem cell mobilization. Blood Rev. 2014; 28(1):31–40.CrossRefGoogle ScholarPubMed

Ding, L, Saunders, TL, Enikolopov, G, Morrison, SJ. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature. 2012; 481(7382):457–62.CrossRefGoogle ScholarPubMed

Broudy, VC. Stem cell factor and hematopoiesis. Blood. 1997; 90(4):1345–64.Google ScholarPubMed

Levesque, JP, Leavesley, DI, Niutta, S, Vadas, M, Simmons, PJ. Cytokines increase human hematopoietic cell adhesiveness by activation of very late antigen (VLA)-4 and VLA-5 integrins. J Exp Med. 1995; 181(5):1805–15.CrossRefGoogle ScholarPubMed

da Silva, MG, Pimentel, P, Carvalhais, A, Barbosa, I, Machado, A, Campilho, F,et al. Ancestim (recombinant human stem cell factor, SCF) in association with filgrastim does not enhance chemotherapy and/or growth factor-induced peripheral blood progenitor cell (PBPC) mobilization in patients with a prior insufficient PBPC collection. Bone Marrow Transplant. 2004; 34(8):683–91.CrossRefGoogle ScholarPubMed

To, LB, Bashford, J, Durrant, S, MacMillan, J, Schwarer, AP, Prince, HM, et al. Successful mobilization of peripheral blood stem cells after addition of ancestim (stem cell factor) in patients who had failed a prior mobilization with filgrastim (granulocyte colony-stimulating factor) alone or with chemotherapy plus filgrastim. Bone Marrow Transplant. 2003; 31(5):371–8.CrossRefGoogle ScholarPubMed

Lapierre, V, Rossi, JF, Heshmati, F, Azar, N, Vekhof, A, Makowski, C, et al. Ancestim (r-metHuSCF) plus filgrastim and/or chemotherapy for mobilization of blood progenitors in 513 poorly mobilizing cancer patients: the French compassionate experience. Bone Marrow Transplant. 2011; 46(7):936–42.CrossRefGoogle ScholarPubMed

De Clercq, E. The bicyclam AMD3100 story. Nat Rev Drug Discov. 2003; 2(7):581–7.CrossRefGoogle ScholarPubMed

Donzella, GA, Schols, D, Lin, SW, Este, JA, Nagashima, KA, Maddon, PJ, et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med. 1998; 4(1):72–7.CrossRefGoogle ScholarPubMed

Devine, SM, Flomenberg, N, Vesole, DH, Liesveld, J, Weisdorf, D, Badel, K, et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin’s lymphoma. J Clin Oncol. 2004; 22(6):1095–102.CrossRefGoogle ScholarPubMed

Flomenberg, N, Devine, SM, DiPersio, JF, Liesveld, JL, McCarty, JM, Rowley, SD, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood. 2005; 106(5):1867–74.CrossRefGoogle Scholar

Calandra, G, McCarty, J, McGuirk, J, Tricot, G, Crocker, SA, Badel, K, et al. AMD3100 plus G-CSF can successful mobilize CD34+ cells from non-Hodgkin’s lymphoma, Hodgkin’s disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant. 2008; 41(4):331–8.CrossRefGoogle ScholarPubMed

Cashen, A, Lopez, S, Gao, F, Calandra, G, MacFarland, R, Badel, K, et al. A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008; 14(11):1253–61.CrossRefGoogle ScholarPubMed

Fowler, CJ, Dunn, A, Hayes-Lattin, B, Hansen, K, Hansen, L, Lanier, K, et al. Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience. Bone Marrow Transplant. 209; 43(12):9–17.

Stiff, P, Micallef, I, McCarthy, P, Magalhaes-Silverman, M, Weisdorf, D, Territo, M, et al. Treatment with plerixafor in non-Hodgkin’s lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. Biol Blood Marrow Transplant. 2009; 15(2):249–56.CrossRefGoogle Scholar

Dugan, MJ, Maziarz, RT, Bensinger, WI, Nademanee, A, Liesveld, J, Badel, K, et al. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin’s lymphoma undergoing stem cell mobilization. Bone Marrow Transplant. 2010; 45(1):39–47.CrossRefGoogle ScholarPubMed

DiPersio, JF, Micallef, IN, Stiff, PJ, Bolwell, BJ, Maziarz, RT, Jacobsen, E, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin’s lymphoma. J Clin Oncol. 2009; 27(28):4767–73.CrossRefGoogle Scholar

DiPersio, JF, Stadtmauer, EA, Nademanee, A, Micallef, IN, Stiff, PJ, Kaufman, JL, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009; 113(23):5720–6.Google ScholarPubMed

Devine, SM, Vij, R, Rettig, M, Todt, L, McGlauchlen, K, Fisher, N, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood. 2008; 112(4):990–8.CrossRefGoogle ScholarPubMed

Rettig, MP, Ansstas, G, DiPersio, JF. Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4. Leukemia. 2012; 26(1):34–53.CrossRefGoogle ScholarPubMed

Nazha, A, Cook, R, Vogl, DT, Mangan, PA, Hummel, K, Cunningham, K, et al. Plerixafor and G-CSF versus cyclophosphamide and G-CSF for stem cell mobilization in patients with multiple myeloma. Blood (ASH Annual Meeting Abstracts). 2009 Dec; 114:Abstract 2146.Google Scholar

Shaughnessy, P, Islas-Ohlmayer, M, Murphy, J, Hougham, M, MacPherson, J, Winkler, K, et al. Plerixafor plus G-CSF compared to chemotherapy plus G-CSF for mobilization of autologous CD34+ cells resulted in similar cost but more predictable days of apheresis and less hospitalization. Blood (ASH Annual Meeting Abstracts). 2009; 114:Abstract 2277.

Fruehauf, S, Veldwijk, MR, Seeger, T, Schubert, M, Laufs, S, Topaly, J, et al. A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study. Cytotherapy. 2009; 11(8):992–1001.CrossRefGoogle ScholarPubMed

Costa, LJ, Alexander, ET, Hogan, KR, Schaub, C, Fouts, TV, Stuart, RK. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant. 2011; 46(1):64–9.Google Scholar

Smith, VR, Popat, U, Ciurea, S, Nieto, Y, Anderlini, P, Rondon, G, et al. Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization. Am J Hematol. 2013; 88(9):754–7.CrossRefGoogle ScholarPubMed

Farina, L, Spina, F, Guidetti, A, Longoni, P, Ravagnani, F, Dodero, A, et al. Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the preemptive use of plerixafor. Leuk Lymphoma. 2014; 55(2):331–6.CrossRefGoogle Scholar

Basak, GW, Mikala, G, Koristek, Z, Jaksic, O, Basic-Kinda, S, Cegledi, A, et al. Plerixafor to rescue failing chemotherapy-based stem cell mobilization: it’s not too late. Leuk Lymphoma. 2011; 52(9):1711–9.CrossRefGoogle Scholar

Vishnu, P, Roy, V, Paulsen, A, Zubair, AC. Efficacy and cost-benefit analysis of risk-adaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization. Transfusion. 2012; 52(1):55–62.CrossRefGoogle ScholarPubMed

Li, J, Hamilton, E, Vaughn, L, Graiser, M, Renfroe, H, Lechowicz, MJ, et al. Effectiveness and cost analysis of “just-in-time” salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. Transfusion. 2011; 51(10):2175–82.CrossRefGoogle ScholarPubMed

Cashen, AF, Lazarus, HM, Devine, SM. Mobilizing stem cells from normal donors: is it possible to improve upon G-CSF? Bone Marrow Transplant. 2007; 39(10):577–88.CrossRefGoogle ScholarPubMed

Anderlini, P, Przepiorka, D, Seong, C, Smith, TL, Huh, YO, Lauppe, J, et al. Factors affecting mobilization of CD34+ cells in normal donors treated with filgrastim. Transfusion. 1997; 37(5):507–12.CrossRefGoogle ScholarPubMed

Grigg, AP, Roberts, AW, Raunow, H, Houghton, S, Layton, JE, Boyd, AW, et al. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. Blood. 1995; 86(12):4437–45.Google ScholarPubMed

Holm, M. Not all healthy donors mobilize hematopoietic progenitor cells sufficiently after G-CSF administration to allow for subsequent CD34 purification of the leukapheresis product. J Hematother. 1998; 7(2):111–3.CrossRefGoogle ScholarPubMed

Platzbecker, U, Prange-Krex, G, Bornhauser, M, Koch, R, Soucek, S, Aikele, P, et al. Spleen enlargement in healthy donors during G-CSF mobilization of PBPCs. Transfusion. 2001; 41(2):184–9.CrossRefGoogle ScholarPubMed

Stroncek, DF, Dittmar, K, Shawker, T, Heatherman, A, Leitman, SF. Transient spleen enlargement in peripheral blood progenitor cell donors given G-CSF. J Transl Med. 2004; 2:25.CrossRefGoogle ScholarPubMed

Horowitz, MM, Confer, DL. Evaluation of hematopoietic stem cell donors. Hematology Am Soc Hematol Educ Program. 2005:469–75.Google Scholar

Nash, RA, Bowen, JD, McSweeney, PA, Pavletic, SZ, Maravilla, KR, Park, MS, et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood. 2003; 102(7):2364–72.CrossRefGoogle ScholarPubMed

Stricker, RB, Goldberg, B. G-CSF and exacerbation of rheumatoid arthritis. Am J Med. 1996; 100(6):665–6.Google ScholarPubMed

Burt, RK, Fassas, A, Snowden, J, van Laar, JM, Kozak, T, Wulffraat, NM, et al. Collection of hematopoietic stem cells from patients with autoimmune diseases. Bone Marrow Transplant. 2001; 28(1):1–12.CrossRefGoogle ScholarPubMed

Gottenberg, JE, Roux, S, Desmoulins, F, Clerc, D, Mariette, X. Granulocyte colony-stimulating factor therapy resulting in a flare of systemic lupus erythematosus: comment on the article by Yang and Hamilton. Arthritis Rheum. 2001; 44(10):2458–60.3.0.CO;2-B>CrossRefGoogle Scholar

Spitzer, G, Adkins, D, Mathews, M, Velasquez, W, Bowers, C, Dunphy, F, et al. Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy. Bone Marrow Transplant. 1997; 20(11):921–30.CrossRefGoogle ScholarPubMed

Gazitt, Y. Comparison between granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the mobilization of peripheral blood stem cells. Curr Opin Hematol. 2002; 9(3):190–8.CrossRefGoogle ScholarPubMed

Rettig, MP, Shannon, WD, Ritchey, J, Holt, M, McFarland, K, Lopez, S, et al. Characterization of human CD34+ hematopoietic stem cells following administration of G-CSF or plerixafor. Blood (ASH Annual Meeting Abstracts). 2008 Dec; 112:Abstract 3476.Google Scholar

Rettig, MP, Lopez, S, McFarland, K, DiPersio, JF. Rapid and prolonged mobilization of human CD34+ hematopoietic stem cells following intravenous (IV) administration of plerixafor. Blood (ASH Annual Meeting Abstracts). 2010 Dec; 116:Abstract 2261.Google Scholar

Kymes, SM, Pusic, I, Lambert, DL, Gregory, M, Carson, KR, DiPersio, JF. Economic evaluation of Plerixafor for stem cell mobilization. Am J Manag Care. 2012; 18(1):33–41.Google ScholarPubMed

Dar, A, Goichberg, P, Shinder, V, Kalinkovich, A, Kollet, O, Netzer, N, et al. Chemokine receptor CXCR4-dependent internalization and resecretion of functional chemokine SDF-1 by bone marrow endothelial and stromal cells. Nat Immunol. 2005; 6(10):1038–46.CrossRefGoogle ScholarPubMed

Imai, K, Kobayashi, M, Wang, J, Shinobu, N, Yoshida, H, Hamada, J, et al. Selective secretion of chemoattractants for haemopoietic progenitor cells by bone marrow endothelial cells: a possible role in homing of haemopoietic progenitor cells to bone marrow. Br J Haematol. 1999; 106(4):905–11.CrossRefGoogle ScholarPubMed

Jung, Y, Wang, J, Schneider, A, Sun, YX, Koh-Paige, AJ, Osman, NI, et al. Regulation of SDF-1 (CXCL12) production by osteoblasts; a possible mechanism for stem cell homing. Bone. 2006; 38(4):497–508.CrossRefGoogle ScholarPubMed

Ponomaryov, T, Peled, A, Petit, I, Taichman, RS, Habler, L, Sandbank, J, et al. Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. J Clin Invest. 2000; 106(11):1331–9.CrossRefGoogle ScholarPubMed

Watt, SM, Forde, SP. The central role of the chemokine receptor, CXC4R, in haemopoietic stem cell transplantation: will CXCR4 antagonists contribute to the treatment of blood disorders? Vox Sang. 2008; 94(1):18–32.Google ScholarPubMed

Peled, A, Petit, I, Kollet, O, Magid, M, Ponomaryov, T, Byk, T, et al. Dependence of human stem cell engraftment and repopulation on NOD/SCID mice on CXCR4. Science. 1999; 283(5403):845–8.CrossRefGoogle ScholarPubMed

Nagasawa, T, Hirota, S, Tachibana, K, Takakura, N, Nishikawa, S, Kitamura, Y, et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature. 1996; 382(6592):635–8.CrossRefGoogle ScholarPubMed

Tachibana, K, Hirota, S, Iizasa, H, Yoshida, H, Kawabata, K, Kataoka, Y, et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature. 1999; 393(6685):591–4.Google ScholarPubMed

Ma, Q, Jones, D, Borghesani, PR, Segal, RA, Nagasawa, T, Kishimoto, T, et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4-and SDF-1-deficient mice. Proc Natl Acad Sci USA. 1998; 95(16):9448–53.CrossRefGoogle ScholarPubMed

Ma, Q, Jones, D, Springer, TA. The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity. 1999; 10(4):463–71.CrossRefGoogle ScholarPubMed

Robinson, JA, Demarco, S, Gombert, F, Moehle, K, Obrecht, D. The design, structures and therapeutic potential of protein epitope mimetics. Drug Discov Today. 2008; 13(21–22):944–51.CrossRefGoogle ScholarPubMed

Schmitt, S, Weinhold, N, Dembowsky, K, Neben, K, Witzens-Harig, M, Braun, M, et al. First results of a phase-II study with the new CXCR4 antagonist POL6326 to mobilize hematopoietic stem cells (HSC) in multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts). 2010 Dec; 116:Abstract 824.Google Scholar

Elices, MJ, Osborn, L, Takada, Y, Crouse, C, Luhowskyj, S, Hemler, ME, et al. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronection binding site. Cell. 1990; 60(4):577–84.CrossRefGoogle Scholar

Scott, LM, Priestley, GV, Papayannopoulou, T. Deletion of alpha4 integrins from adult hematopoietic cells reveals roles in homeostasis, regeneration, and homing. Mol Cell Biol. 2003; 23(24):9349–60.CrossRefGoogle ScholarPubMed

Priestley, GV, Ulyanova, T, Papayannopoulou, T. Sustained alterations in biodistribution of stem/progenitor cells in Tie2Cre+ alpha4(f/f) mice are hematopoietic cell autonomous. Blood. 2007; 109(1):109–11.CrossRefGoogle ScholarPubMed

Priestley, GV, Scott, LM, Ulyanova, T, Papayannopoulou, T. Lack of alpha4 integrin expression in stem cells restricts competitive function and self-renewal activity. Blood. 2006; 107(7):2959–67.CrossRefGoogle ScholarPubMed

Jing, D, Oelschlaegel, U, Ordemann, R, Holig, K, Ehninger, G, Reichmann, H, et al. CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function. Bone Marrow Transplant. 2010; 45(10):1489–96.CrossRefGoogle ScholarPubMed

Zohren, F, Toutzaris, D, Klarner, V, Hartung, HP, Kieseier, B, Haas, R. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood. 2008; 111(7):3893–5.CrossRefGoogle ScholarPubMed

Foley, J. Recommendations for the selection, treatment, and management of patients utilizing natalizumab therapy for multiple sclerosis. Am J Manag Care. 2010; 16(6 Suppl):S178–83.Google ScholarPubMed

Ransohoff, RM. Natalizumab for multiple sclerosis. N Engl J Med. 2007; 356(25):2622–9.CrossRefGoogle ScholarPubMed

Davenport, RJ, Munday, JR. Alpha4-integrin antagonism − an effective approach for the treatment of inflammatory diseases? Drug Discov Today. 2007; 12(13–14):569–76.CrossRefGoogle ScholarPubMed

Jackson, DY. Alpha 4 integrin antagonists. Curr Pharm Des. 2002; 8(14):1229–53.CrossRefGoogle ScholarPubMed

Yang, GX, Hagmann, WK. VLA-4 antagonists: potent inhibitors of lymphocyte migration. Med Res Rev. 2003; 23(3):369–92.CrossRefGoogle ScholarPubMed

Ghosh, S, Panaccione, R. Anti-adhesion molecule therapy for inflammatory bowel disease. Therap Adv Gastroenterol. 2010; 3(4):239–58.CrossRefGoogle ScholarPubMed

Takazoe, M, Watanabe, M, Kawaguchi, T, Matsumoto, T, Oshitani, N, Hiwatashi, N, et al. Oral alpha-4 integrin inhibitor (AJM300) in patients with active Crohn’s disease – a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2009; 136(5 Suppl 1):A-181CrossRefGoogle Scholar

Muro, F, Iimura, S, Sugimoto, Y, Yoneda, Y, Chiba, J, Watanabe, T, et al. Discovery of trans-4-[1-[[2,5-Dichloro-4-(1-methyl-3-indolylcarboxamido)phenyl]acetyl]-(4S)-methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid: an orally active, selective very late antigen-4 antagonist. J Med Chem. 2009; 52(24):7974–92.CrossRefGoogle ScholarPubMed

Ramirez, P, Rettig, MP, Uy, GL, Deych, E, Holt, MS, Ritchey, JK, et al. BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells. Blood. 2009; 114(7):1340–3.CrossRefGoogle ScholarPubMed

King, AG, Johanson, K, Frey, CL, DeMarsh, PL, White, JR, McDevitt, P, et al. Identification of unique truncated KC/GROβ chemokines with potent hematopoietic and anti-infective activities. J Immunol. 2000; 164(7):3774–82.CrossRefGoogle Scholar

King, AG, Horowitz, D, Dillon, SB, Levin, R, Farese, AM, MacVittie, TJ, et al. Rapid mobilization of murine hematopoietic stem cells with enhanced engraftment properties and evaluation of hematopoietic progenitor cell mobilization in rhesus monkeys by a single injection of SB-251353, a specific truncated form of the human CXC chemokine GROβ. Blood. 2001; 97(6):1534–42.CrossRefGoogle ScholarPubMed

Pelus, LM, Bian, H, King, AG, Fukuda, S. Neutrophil-derived MMP-9 mediates synergistic mobilization of hematopoietic stem and progenitor cells by the combination of G-CSF and the chemokines GROβ/CXCL2 and GROβT/CXCL2Δ4. Blood. 2004; 103(1):110–9.CrossRefGoogle ScholarPubMed

Pelus, LM, Fukuda, S. Peripheral blood stem cell mobilization: the CXCR2 ligand GROβ rapidly mobilizes hematopoietic stem cells with enhanced engraftment properties. Exp Hematol. 2006; 34(8):1010–20.CrossRefGoogle ScholarPubMed

Osawa, M, Hanada, K, Hamada, H, Nakauchi, H. Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. Science. 1996; 273(5272):242–5.CrossRefGoogle ScholarPubMed

Matsuzaki, Y, Kinjo, K, Mulligan, RC, Okano, H. Unexpectedly efficient homing capacity of purified murine hematopoietic stem cells. Immunity. 2004; 20(1):87–93.CrossRefGoogle ScholarPubMed

Fukuda, S, Bian, H, King, AG, Pelus, LM. The chemokine GROβ mobilizes early hematopoietic stem cells characterized by enhanced homing and engraftment. Blood. 2007; 110(3):860–9.CrossRefGoogle ScholarPubMed

Sackstein, R. The lymphocyte homing receptors: gatekeepers of the multistep paradigm. Curr Opin Hematol. 2005; 12(6):444–50.CrossRefGoogle ScholarPubMed

Wodnar-Filipowicz, A. Flt3 ligand: role in control of hematopoietic and immune functions of the bone marrow. News Physiol Sci. 2003; 18:247–51.Google ScholarPubMed

He, S, Chu, J, Vasu, S, Deng, Y, Yuan, S, Zhang, J, et al. FLT3L and Plerixafor combination increases hematopoietic stem cell mobilization and leads to improved transplantation outcome. Biol Blood Marrow Transplant. 2014; 20(3):309–13.CrossRefGoogle ScholarPubMed

Olson, JA, Leveson-Gower, DB, Gill, S, Baker, J, Beilhack, A, Negrin, RS. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood. 2010; 115(21):4293–301.CrossRefGoogle ScholarPubMed

Rezvani, K, Mielke, S, Ahmadzadeh, M, Kilical, Y, Savani, BN, Zeilah, J, et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood. 2006; 108(4):1291–7.CrossRefGoogle ScholarPubMed

Anandasabapathy, N, Hurley, A, Breton, G, Caskey, M, Trumpfheller, C, Sarma, P, et al. A phase 1 trial of the hematopoietic growth factor CDX-301 (rhuFlt3L) in healthy volunteers. Biol Blood Marrow Transplant. 2013; 19(2 Suppl):S112–S113.CrossRefGoogle Scholar

Hill, JM, Zalos, G, Halcox, JP, Schenke, WH, Waclawiw, MA, Quyyumi, AA, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003; 348(7):593–600.CrossRefGoogle ScholarPubMed

Khan, SS, Solomon, MA, McCoy, JP Jr. Detection of circulating endothelial cells and endothelial progenitor cells by flow cytometry. Cytometry B Clin Cytom. 2005; 64(1):1–8.CrossRefGoogle ScholarPubMed

Wojakowski, W, Landmesser, U, Bachowski, R, Jadczyk, T, Tendera, M. Mobilization of stem and progenitor cells in cardiovascular diseases. Leukemia. 2012; 26(1):23–33.CrossRefGoogle ScholarPubMed

Asahara, T, Takahashi, T, Masuda, H, Kalka, C, Chen, D, Iwaguro, H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 1999; 18(14):3964–72.CrossRefGoogle ScholarPubMed

Schroder, K, Kohnen, A, Aicher, A, Liehn, EA, Buchse, T, Stein, S, et al. NADPH oxidase Nox2 is required for hypoxia-induced mobilization of endothelial progenitor cells. Circ Res. 2009; 105(6):537–44.CrossRefGoogle ScholarPubMed

Lundby, C, Gassmann, M, Pilegaard, H. Regular endurance training reduces the exercise induced HIF-1α and HIF-2α mRNA expression in human skeletal muscle in normoxic conditions. Eur J Appl Physiol. 2006; 96(4):363–9.CrossRefGoogle ScholarPubMed

Cubbon, RM, Murgatroyd, SR, Ferguson, C, Bowen, TS, Rakobowchuk, M, Baliga, V, et al. Human exercise-induced circulating progenitor cell mobilization is nitric oxide-dependent and is blunted in South Asian men. Arterioscler Thromb Vasc Biol. 2010; 30(4):878–84.CrossRefGoogle ScholarPubMed

Hambrecht, R, Adams, V, Erbs, S, Linke, A, Krankel, N, Shu, Y, et al. Regular physical activity improves endothelial function in patients with coronary artery disease by increasing phosphorylation of endothelial nitric oxide synthase. Circulation. 2003; 107(25):3152–8.CrossRefGoogle ScholarPubMed

Bonsignore, MR, Morici, G, Riccioni, R, Huertas, A, Petrucci, E, Veca, M, et al. Hemopoietic and angiogenetic progenitors in healthy athletes: different responses to endurance and maximal exercise. J Appl Physiol (1985). 2010; 109(1):60–7.CrossRefGoogle ScholarPubMed

Jenkins, NT, Witkowski, S, Spangenburg, EE, Hagberg, JM. Effects of acute and chronic endurance exercise on intracellular nitric oxide in putative endothelial progenitor cells: role of NADPH oxidase. Am J Physiol Heart Circ Physiol. 2009; 297(5):H1798–805.CrossRefGoogle Scholar

Halme, DG, Kessler, DA. FDA regulation of stem cell based therapies. N Engl J Med. 2006;355(16):1730–5.CrossRefGoogle ScholarPubMed

The Code of Federal Regulations. Human cells, tissues and cellular and tissue-based products. 2014; Part 1271.

Eapen, M, O’Donnell, P, Brunstein, CG, Wu, J, Barowski, K, Mendizibal, A et al. Mismatched related and unrelated donors for allogeneic hematopoietic cell transplantation for adults with hematologic malignancies. Biol Blood Marrow Transplant. 2014;20(10):1485–92.CrossRefGoogle ScholarPubMed

Mielke, S, McIver, ZA, Shenoy, , Fellowes, V, Khuu, H, Stroncek, DF et al. Selectively T cell depleted allografts from HLA-matched sibling donors followed by low-dose posttransplantation immunosuppression to improve transplantation outcome in patients with hematologic malignancies. Biol Blood Marrow Transplant. 2011;17(12): 1855–61.CrossRefGoogle ScholarPubMed

Berz, D, McCormack, EM, Winer, ES, Colvin, GA, Quesenberry, PJ. Cryopreservation of hematopoietic stem cells. Am J Hematol. 2007;82(6): 463–72.CrossRefGoogle ScholarPubMed

Melillo, L, Cascavilla, N, Lerma, E, Corsetti, MT, Carella, AM. The significance of minimal residual disease in stem cell grafts and the role of purging: is it better to purge in vivo or in vitro? Acta Haematol 2005;114(4): 206–13.CrossRefGoogle ScholarPubMed

Sidney, LE, Branch, MJ, Dunphy, SE, Dua, HS, Hopkinson, A. Concise review: evidence for CD34 as a common marker for diverse progenitors. Stem Cells. 2014;32(6):1380–9.CrossRefGoogle ScholarPubMed

Basel, MT, Shrestha, TB, Bossmann, SH, Troyer, DL. Cells as delivery vehicles for cancer therapeutics. Ther Deliv. 2014;5(5):555–67.CrossRefGoogle ScholarPubMed

Lapteva, N, Vera, JF. Optimization manufacture of virus and tumor-specific T cells. Stem Cells Int. 2011;2011:434392. doi: 10.4061/2011/434392. Epub 2011 Sep 11.CrossRefGoogle ScholarPubMed

Gulen, D, Abe, F, Maas, S, Reed, E, Cowan, K, Pirruccello, S et al. Closing the manufacturing process of dendritic cell vaccines transduced with adenovirus vectors. Int Immunopharmacol. 2008;8(13–14):1728–36.CrossRefGoogle ScholarPubMed

Donia, M, Larsen, SM, Met, O, Svane, IM. Simplified protocol for clinical grade tumor-infiltrating lymphocyte manufacturing with use of the Wave bioreactor. Cytotherapy. 2014;16(8):1117–20.CrossRefGoogle ScholarPubMed

Hanley, PJ, Mei, Z, Durett, AG, de Graca Cabreira-Harrison, M, Klis, M, Li, W et al. Efficient manufacturing of therapeutic mesenchymal stromal cells with the use of the Quantum cell expansion system. Cytotherapy. 2014;16(8):1048–58.CrossRefGoogle Scholar

Tapia, F, Vogel, T, Genzel, Y, Behrendt, I, Hirschel, M, Gangemi, JD et al. Production of high-titer influenza A virus with adherent and suspension MDCK cells cultured in a single use hollow fiber bioreactor. Vaccine. 2014;32(8):1003–11.CrossRefGoogle Scholar

Canovas, D, Bird, N. Human AB serum as an alternative to fetal bovine serum for endothelial and cancer cell culture. ALTEX 2012;29(4):426–8.CrossRefGoogle ScholarPubMed

Read, E. Ancillary materials for cell and tissue-based products. US Pharmacopeia. Available from: http://c.ymcdn.com/sites/www.celltherapysociety.org/resource/resmgr/uploads/files/Cell Therapy Liaison Meetings/November 2011/2. CTLM_Read_29MOV2011.pdf

Winter, JM, Jacobson, P, Bullough, B, Christensen, AP, Boyer, M, Reems, JA. Long-term effects of cryopreservation on clinically prepared hematopoietic progenitor cell products. Cytotherapy. 2014;16(7):965–75.CrossRefGoogle ScholarPubMed

Miller, JS, Rooney, CM, Curtsinger, J, McElmurry, R, McCullar, V, Verneris, MR et al. Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy. Biol Blood Marrow Transplant. 2014;20(8):1252–7. doi: 10.1016/j.bbmt.2014.05.004. Epub 2014 May 9.CrossRefGoogle ScholarPubMed

Lapteva, N, Szmania, SM, van Rhee, F, Rooney, CM. Clinical grade purification and expansion of natural killer cells. Crit Rev Oncol. 2014:19(1–2):121–32.Google ScholarPubMed

Shu, Z, Heimfeld, S, Gao, D. Hematopoietic SCT with cryopreserved grafts: adverse reactions after transplantation and cryoprotectant removal before infusion. Bone Marrow Transplant. 2014;49(4):469–76.CrossRefGoogle ScholarPubMed

Kozma, N, Speletz, H, Reiter, U, Lanzer, G, Wagner, T. Impact of 13.56-MHz radiofrequency identification systems on the quality of stored red blood cells. Transfusion. 2011;51(11):2384–90.CrossRefGoogle ScholarPubMed

Bielanski, A. Non-transmission of bacterial and viral microbes to embryos and semen stored in vapour phase of liquid nitrogen dry shippers. Cryobiology. 2005;50(2):206–10.CrossRefGoogle ScholarPubMed

Veronesi, E, Murgia, A, Caselli, A, Grisendi, G, Picinno, MS, Rasini, V et al. Transportation conditions for prompt use of ex vivo expanded and freshly harvested clinical-grade bone marrow mesenchymal stromal/stem cells for bone regeneration. Tissue Eng Part C Methods. 2014;20(3):239–51.CrossRefGoogle ScholarPubMed

Klingemann, H, Grodman, C, Cutler, E, Duque, M, Kadidlo, D, Klein, AK et al. Autologous stem cells transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusion. Transfusion. 2013;53(2):412–8.CrossRefGoogle Scholar

Eggenhofer, E, Popp, FC, Mendicino, M, Silber, P, Van’t Hof, W, Renner, P et al. Heart grafts tolerized through third-party multipotent cells can be retransplanted to secondary hosts with no immunosuppression. Stem Cells Transl Med. 2013;2(8):595–606.CrossRefGoogle ScholarPubMed

Leen, AM, Bollard, CM, Mendizabal, AM, Shpall, EJ, Szabolics, P, Antin, JH et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013;121(26):5113–23.CrossRefGoogle ScholarPubMed